Jiren Yu

机构：Hangzhou First People's Hospital, First Affiliated Hospital Zhejiang University · ORCID：0000-0002-7904-107X

发表论文 87 篇 · 总被引 1802 次 · h-index 22

代表论文

• Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 56)
• Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial. (2025 · Journal of Clinical Oncology · 被引 28)
• LBA78 Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial (2023 · Annals of Oncology · 被引 14)
• Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis (2025 · Gastric Cancer · 被引 7)
• CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors (2023 · European Radiology · 被引 6)
• Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China (2023 · Advances in Therapy · 被引 4)